Current Assets
Available For Sale Securities Debt Securities Current
Bristol-Myers Squibb Available For Sale Securities Debt Securities Current decreased by 9.6% to $464.00M in Q4 2025 compared to the prior quarter.
Analysis
StatementBalance Sheet Statement
SectionCurrent Assets
CategoryLiquidity
SignalContext dependent
VolatilityModerate
First reportedQ4 2024
Last reportedQ1 2026
How to read this metric
An increase suggests higher liquidity and a conservative cash management strategy, while a decrease may indicate the use of cash for operations or acquisitions.
Detailed definition
This represents the fair value of debt securities held by the company that are classified as available-for-sale and are...
Peer comparison
Commonly reported by large-cap technology firms as 'Short-term investments' or 'Available-for-sale securities'.
Metric ID:
current_assets_available_for_sale_securities_debt_securi_87ec82Historical Data
2 periods
| Q4 '24 | Q4 '25 | |
|---|---|---|
| Value | $513.00M | $464.00M |
| QoQ Change | — | -9.6% |
| YoY Change | — | -9.6% |
Range$464.00M – $513.00M
Avg YoY Growth-9.6%
Median YoY Growth-9.6%
Available For Sale Securities Debt Securities Current at Other Companies
Frequently Asked Questions
- What is Bristol-Myers Squibb's available for sale securities debt securities current?
- Bristol-Myers Squibb (BMY) reported available for sale securities debt securities current of $464.00M in Q4 2025.
- What does available for sale securities debt securities current mean?
- The value of short-term debt investments that the company intends to sell within a year.